
Marker Therapeutics, Inc. Common Stock
MRKR
MRKR: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
moreShow MRKR Financials
Recent trades of MRKR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MRKR's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on MRKR's company Twitter account
Number of mentions of MRKR in WallStreetBets Daily Discussion
Recent insights relating to MRKR
Recent picks made for MRKR stock on CNBC
ETFs with the largest estimated holdings in MRKR
Flights by private jets registered to MRKR